Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Absurd COVID-19 Vaccine Regulatory Race

Executive Summary

Donald Trump is no longer the only one who thinks the US FDA is moving too slow on allowing broad access to COVID-19 vaccine candidates. But before the narrative that FDA’s caution cost lives takes root, let’s remember the facts: the key milestone isn’t when an effective vaccine is authorized, but when supplies are sufficient to mount an effective vaccination campaign.

You may also be interested in...

Possibility Of COVID Vaccine Production Glitches Drives Early US Dose Distribution Plan

Initial allocation plans for the Pfizer/BioNTech vaccine may change after a month or so if manufacturing scaleup proceeds ‘perfectly,’ Operation Warp Speed’s Slaoui suggests.

Flexibility And Agility Key To Speedy UK COVID Vaccine Approval

The flexibility and agility of parallel teams of scientists and clinicians who worked around the clock were key to speedy UK approval of the COVID-19 vaccine, according to UK agency head June Raine. Canada has also just announced that it has approved the Pfizer/BioNTech vaccine.

Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes

Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts